

MONDAY 3RD JUNE

Pre-conference Meetings

- Association of Nephrology Nurses UK
- NIHR/KRUK industry
- South of England Kidney Quality Improvement Partnership (KQuIP) Half Day
- Association of Renal Managers
- Renal Society working party imaging session (joint with the Microscopy Society)
- Paediatric CSG
- UK Renal Imaging Network

11:00

Registration opens

11:30-12:45

Lunch and exhibition

11:30-12:30

Corporate session – Napp Pharmaceuticals

Corporate session – Boehringer Ingelheim

Dysfunctional CVCs and clearing thrombotic occlusions

Louise Oakaby a specialist nurse from Royal Devon and Exeter NHS Foundation Trust will talk about dysfunctional CVCs and answer all your Cathflo questions.

12:45-14:00

Plenary Session: Genetics and precision medicine

Welcome from Graham Lipkin; President of the Renal Association and Sharlene Greenwood, President-Elect of the British Renal Society

The DNA Sequencer will see you now: lessons from diabetes

Professor Andrew Hattersley, Consultant Diabetologist at the Royal Devon and Exeter Hospital and the Professor of Molecular Medicine at the University of Exeter

The importance of genetics for diagnosis and management of rare renal disorders

Professor Nine Knoers, Clinical Geneticist, chair department Genetics University Medical Centre Groningen, University Medical Centre Groningen, The Netherlands

14:10-15:40

Three minute heroes

16 posters delivered in three minute presentations

49 - *Clinical Practice Guideline: Monitoring children and young people with, and at risk of developing Autosomal Dominant Polycystic Kidney Disease (ADPKD),*

Direct (non vitamin-K) oral anticoagulants (DOACs) in kidney disease

Chair: Hayley Wells and Sue Shaw

DOACs – what are they, how are they used, and will they replace warfarin? - Jecko Thachil, Consultant haematologist

Kidney Transplantation: Recipient, donor, and organ assessment; practical aspects for clinical care

Chair: Nicholas Torpey and Lorna Mason

Trends and projections for deceased donors and transplants - Lisa Mumford

The cutting edge of Quality Improvement: tools for kidney care

Using structure and finance to drive quality improvement – Dr Clara Day, Nephrology Consultant, University Hospitals Birmingham NHS Trust

Future influences on anaemia management in CKD

Chair: Lesley Bennett and Karen Jenkins

Undertaking research within routine clinical practice: experiences from the PIVOTAL study - Alison Blythin, Renal and Research Nurse Specialist, Wessex Kidney Centre

Renal stone disease, diagnosis and management

Chair: Robert Unwin

Common stone disease – diagnosis and management – Andrew Connor

Rare stone disease – recognition and treatment –

“It’s Friday, its 5pm and the phone rings....”

Chair: Marie Condon and Alex Riding

A young male with pulmonary-renal syndrome – approach to diagnosis and management – Dr Stephen McAdoo, Consultant Nephrologist, Imperial College London

<p>Marlais Matko, UCL Great Ormond Street Institute Of Child Health</p> <p>266 - <i>The Prepare for Kidney Care Randomised Controlled Trial: Background, Intervention, Outcome Measures and Progress</i>, Helen Winton, University of Bristol</p> <p>192 - <i>Randomised Controlled Trial Protocol: The Use of Rituximab In the treatment of Nephrotic Glomerulonephritis (TURING)</i> – Lisa Wilcocks, Cambridge University Hospitals NHS Foundation Trust</p> <p>422 - <i>Assist-HHD Study: A feasibility study into staff-assisted Home Hemodialysis (aHHD) as an alternative dialysis modality</i> – Kunaal Kharbanda, Manchester University Hospitals</p> <p>464 - <i>Long term outcomes of rituximab treatment in membranous nephropathy</i> – Aikaterini Nikolopoulou, Imperial College</p>	<p><i>DOACs in chronic kidney disease (including ESRD), current considerations</i> – Rachna Bedi, Renal Pharmacist</p> <p><i>Atrial Fibrillation in CKD, how should we be using DOACS?</i> - Professor Charlie Ferro, Professor of Nephrology</p> <p>Round table discussion</p> <p>BRS/RA Education CPD</p>	<p><i>Expert MDT panel</i> Lorna Marson, BTS President Menna Clatworthy Chris Callaghan, transplant surgeon at Guy's, and NHSBT lead for organ utilization Dr Stephen Marks, Paediatric nephrologist at Great Ormond Street</p> <p><i>The future of donor organ assessment</i> - Menna Clatworthy</p> <p>BTS co-badged session</p>	<p>Dr William McKane, Consultant Nephrologist, Sheffield Teaching Hospitals NHSFT and Kerry Tomlinson</p> <p><i>MAGIC: How do we improve cannulation for haemodialysis patients?</i> – Katie Fielding, Haemodialysis Nurse, University Hospitals of Derby and Burton NHS Foundation Trust</p> <p><i>Using PREMs to drive QI</i> – Rachel Gair, Quality Improvement Manager, UK Renal Registry</p> <p>319 - <i>Lessons learned from the development and evaluation of a virtual renal clinic</i> – Sally Hull, Queen Mary University, London</p> <p>520 - <i>Introducing a tool to implement Transplant First: Identifying barriers to transplant listing, measuring for improvement, and lessons learned from a pilot centre</i> – Dr Kerry Tomlinson, University Hospitals North Midlands</p>	<p><i>The PIVOTAL trial: A tipping point in iron management</i> - Professor David Wheeler, Professor of Kidney Medicine, University College London</p> <p><i>FGF23: At the Intersection of Phosphate and Iron Homeostasis</i> - Professor Myles Wolf, Duke University School of Medicine.</p> <p>85 - <i>The effect of initiation of renin-angiotensin system inhibitors on haemoglobin</i> – George Greenhall, London School of Hygiene and Tropical Medicine</p> <p>308 - <i>IV iron dosing and infection risk in the PIVOTAL trial: a pre-specified secondary analysis</i> – Professor Sunil Bhandari, Consultant Nephrologist, Hull and East Yorkshire Hospitals NHS Trust</p> <p>ANSA co-badged session supported by Pharmacosmos & Kidney Research UK</p>	<p>Professor John Sayer, Professor of Renal Medicine, Newcastle University</p> <p><i>A Medical Stone Clinic - Does your unit need one?</i> – Dr Shabbir Moochhala, Consultant Nephrologist, Royal Free Hospital</p> <p>124 - <i>Natural history, outcomes and mortality associations of calciphylaxis: Update from the UK calciphylaxis registry</i> – Rajkumar Chinnadurai, Salford Royal NHS Foundation Trust</p> <p>25 - <i>Clinical and biochemical characteristics of hypokalaemic patients: predictors of a genetic diagnosis of Gitelman or Bartter syndrome</i> – Elizabeth Wan, Royal Free Hospital</p> <p>31 - <i>24-hour versus spot urinary sodium and potassium measurements in adult hypertensive patients: a cohort validation study</i> - Elizabeth Wan, Royal Free Hospital</p>	<p><i>Haemolytic anaemia and thrombocytopenia – what do I do now?</i> – Dr Edwin Wong, Consultant Nephrologist, National Renal Complement Therapeutics Centre</p> <p><i>A pregnant woman with CKD now with worsening hypertension and proteinuria: management of pre-eclampsia in the woman with CKD</i> – Dr Katie Bramham, Consultant Nephrologist, Kings Kidney Care, Kings College London</p>
--	---	--	--	---	--	---

MONDAY 3RD JUNE (continued)

14:10-15:40

57 - *Multi-morbidity patterns in patients with non-dialysis chronic kidney disease across England: a multi-centre cluster analysis* – Thomas Wilkinson, University of Leicester

187 - *X-linked Alport syndrome in the genomic medicine era - uncovering unusual clinical phenotypes of COL4A5 variants* – Abhijit Dixit, Nottingham University Hospitals NHS Trust

97 - *Multiparametric Renal MRI to Assess Structure and Function in Chronic Kidney Disease* - Rebecca Noble, The University Of Nottingham

162 - *ABT-263 administration depletes radiation induced senescent cells and reduces renal fibrosis after subsequent injury* – Katie Mylonas, University Of Edinburgh

164 - *Ankyrin Repeat and Single KH domain 1 (ANKHD1) is a novel driver of polycystic kidney disease in vivo* – Maria Fragiadaki, University Of Sheffield

442 - *The Kidney Quality Improvement Partnership (KQuIP): Developing and embedding Quality Improvement capability within the kidney community – a local, regional, and national approach* – Rachel Gair, UK Renal Registry – Renal Association

349 - *The role of the calprotectin/ RAGE/ TLR4 axis in ANCA-Associated vasculitis* – Theresa Page, Imperial College

408 - *Vascular endothelial growth factor-C (VEGF-C) reduces cystogenesis in a human cellular model of polycystic kidney disease generated by CRISPR technology* – Nuria Perretta Tejedor, University College London

414 - *Complement in membranous nephropathy* – Aikaterini Nikolopoulou, Imperial College

198 - *Gene polymorphisms associated with microalbuminuria in 396,812 individuals from the UK Biobank cohort* – Marisa Canadas Garre, Queen's University of Belfast

399 - *JAK2 inhibition halts the growth of polycystic kidney disease-derived epithelial cysts in vitro* – Maria Fragiadaki, University of Sheffield

491 - *The role of GATA3 in bone morphogenetic protein 7 (BMP7) dependent prevention and*

MONDAY 3RD JUNE (continued)

reversal of myofibroblast phenotype – Irina Grigorieva, Cardiff University

15:40-16:10 **Tea/coffee break and exhibition**

16:10-17:10 **Corporate session – AstraZeneca**

Corporate session – Sanofi

Undiagnosed Renal Disease: Deciphering the Clinical Clues

Chair: Professor Bruce Hendry

Professor John Sayer, Professor of Renal Medicine, Newcastle University

Dr Shalabh Srivastava, Consultant Nephrologist South Tyneside and Sunderland NHS Foundation Trust & Associate Clinical Lecturer, Newcastle University

Significant number of patients with Chronic Kidney Disease (CKD) will be diagnosed with a rare renal disease each year. However, the diagnostic delay for these patients can be long, lasting for up to 13 years¹. This symposium focuses on the importance of unravelling the clinical cues to identify rare renal disease in patients with undiagnosed CKD. Clinical cases will be used to highlight the important role of the nephrologist in recognising the renal signs and symptoms of these rare conditions. Timely diagnosis and treatment remain critical to optimise management and improve outcomes for patients.

Working together to understand fibrosis and regeneration

Chair: Jamie Davies and Jill Norman

Assessing the efficacy and safety of cell therapies in preclinical models of kidney – Bettina Wilm

Working together to bridge the gap to translation – Dr Claire Sharpe, Reader in Renal Medicine, King's College London/King's College Hospital

The potential of whole organ MRI and non-invasive assessment of renal fibrosis – Professor Susan Francis, Professor of MR Physics, University of Nottingham

The patient perspective

17:15-17:45 **Highlights of Day One**

17:45-19:00 **Welcome reception and networking in exhibition hall**

18:00 **Fun Run** - Join us on the promenade directly outside the Hilton Brighton Metropole Hotel for a 5K run along Brighton seafront. Registration will need to be completed beforehand.

07:00-08:00

Registration opens

08:00-08:45

Corporate session – Alexion

Establishing a tailored treatment strategy in aHUS – the need for an evidence-based approach

Professor David Kavanagh, Professor of Complement Therapeutics and Honorary Consultant Nephrologist at the National Renal Complement Therapeutics Centre, Newcastle upon Tyne

Professor Neil Sheerin, Professor of Nephrology at Newcastle University and Consultant Nephrologist at the Freeman Hospital, Newcastle upon Tyne

Please join aHUS expert speakers Professor David Kavanagh and Professor Neil Sheerin, at this Alexion-sponsored symposium, where they will present on challenges related to timely diagnosis of disease, the impact of genetics and the role of the national aHUS service. The symposium will also seek to address the widely-debated topic of the optimal treatment duration in aHUS and the need for an evidence-based strategy that allows for safe withdrawal of treatment in appropriate patients with timely reintroduction in those that relapse.

Corporate session – Otsuka

08:50-10:00

Plenary Session

Chair: Philip Kalra and Ellen Castle

Professor Steve Powis, National Medical Director of NHS England and Professor of Renal Medicine at University College London.

Professor Myles Wolf, Professor of Medicine and Chief of the Division of Nephrology at the Duke University School of Medicine.

10:00-10:30

Tea/coffee break and exhibition

10:30-12:00

Best Clinical and Scientific abstracts

Chair: Gavin Welsh

Chandos Lecture: *Reimagining clinical care in ADPKD for the 21st century?* - Professor Albert Ong, Professor of Renal Medicine, University of Sheffield

Reproductive health and the kidney

Chair: Liz Lightstone and Lucy Chappell

My pregnancy, my transplant and my dialysis – Germin Mohamed and Dr Matthew Hall, Consultant Nephrologist,

Renal hypertension Current evidence, current challenges

Fibromuscular Dysplasia – Rare or Underdiagnosed? - Dr Tina Chrysochou, Consultant Nephrologist, Salford Royal Hospitals NHS Foundation Trust

TIME to change physical activity, salt and fluid intake behaviours

Chairs: Bruno Mafirci and Ellen Castle

TIME to change behaviour- techniques to assist with behaviour change

BRS/KCUK Research Symposium session

Donna Lamping Lecture – Enric Vilar

A novel integrative surveillance model for kidney transplant patients - Dr Antonia Cronin,

AKI: the role of diagnostics in the development of new therapeutics

Chair: Nick Selby and Andrew Lewington

AKI biomarkers, where are we now? –

UK Renal Trials Network Update: Do you know how to design and interpret a clinical trial?

Chair: Will Herrington and Phil Kalra

How to design and conduct a trial – Dr Richard Haynes,

Transplantation: Oral abstracts

AMR focus: UK AMR trial and emerging novel therapies - Michelle Willicombe Imperial College Healthcare NHS Trust

TUESDAY 4TH JUNE (continued)

10:30-12:00	<p>334 - <i>MinTac: A prospective, multicentre, randomised controlled trial of tacrolimus vs prednisolone for adults with de novo minimal change disease</i> – Nicholas Medjeral-Thomas, Imperial College</p> <p>517 - <i>The impact of utilising the Kidney Failure Risk Equation for referral into secondary care for individuals with chronic kidney disease in the UK</i> – Paul Cockwell, Queen Elizabeth Hospital Birmingham</p> <p>76 - <i>Physical activity and exercise behaviours of peritoneal dialysis patients in England: results from a multicentre observational trial</i> – Courtney Lightfoot, University of Leicester</p>	<p>Nottingham University Hospitals</p> <p><i>I have CKD. Can I get pregnant?</i> – Dr Kate Bramham, Consultant Nephrologist, King's Kidney Care / King's College London</p> <p><i>If I do, what will happen to my kidneys?</i> – Kate Wiles</p> <p><i>Are my drugs safe?</i> – Professor Catherine Nelson-Piercy, Professor of Obstetric Medicine, Guy's & St Thomas' Foundation Trust and Imperial College health care Trust</p> <p><i>Do I have pre-eclampsia or renal disease?</i> – Professor Lucy Chappell</p> <p>Q&A time</p> <p>BRS/RA Education CPD</p>	<p><i>An update on device-based therapy of hypertension</i> - Dr Vikas Kapil</p> <p><i>New approaches to curing a common cause of Hypertension – Primary Aldosteronism</i> - Professor Morris Brown</p>	<p>– Julie Denning</p> <p><i>Physical activity as a health behaviour in Chronic Kidney Disease</i> – Dr Pelagia Koufaki, Research Fellow, Centre for Health, Physical Activity and Rehabilitation Research, Queen Margaret University, Edinburgh</p> <p><i>Time to refresh - an update on Fluid and Salt Management</i> – Lakshmi Chandrasekharan, Lead Renal & Diabetes Specialist, Southend University Hospital NHS Foundation</p> <p>398 - <i>Development and implementation of MOVE: making exercise part of routine care for dialysis patients</i> – Jennifer Cooney, Bangor University</p>	<p>Consultant Nephrologist and Honorary Senior Lecturer, Guy's Hospital;</p> <p><i>A pilot study on the impact of peer support for people with advanced kidney failure presenting late to renal services</i> - Eleri Wood, Consultant Nurse, Kings College Hospital</p> <p><i>Patient perspectives of target weight management and ultrafiltration during haemodialysis</i> - Dr David Keane, Clinical Scientist, St James Hospital, Leeds</p> <p><i>From small beginnings to research impact: How charity-funded projects can directly benefit patients and society, and pave the way for longer and larger grants</i> - Professor Veronica Swallow, Professor in Child, Young Person and Family Health, University of Leeds</p>	<p>Professor Rosamonde Banks, Professor of Biomedical Proteomics, Leeds Institute of Medical Research at St James's, University of Leeds</p> <p><i>On the Horizon – novel therapeutics for AKI</i> – Dr Chris Laing</p> <p><i>Epidemiology of paediatric AKI, differences and similarities with adult AKI</i> – Dr David Milford, Consultant Paediatric Nephrologist, Birmingham Women's and Children's Hospital</p> <p>378 - <i>The Impact of Acute Kidney Injury Requiring Haemodialysis on Patient Survival: 10 years of Prospective Data - An Australian Perspective</i> – Benjamin Talbot, The George Institute for Global Health</p>	<p>Associate Professor, University of Oxford</p> <p><i>ISN-ACT trial toolkit</i> – Dr Thomas Hiemstra, University Lecturer in Trials, Honorary Consultant Nephrologist University of Cambridge</p> <p><i>How a patient might want to be involved in trial design and conduct</i> – Dr Claire Corps, Research Scientist, Leeds Teaching Hospitals NHS Trust</p> <p><i>How to analyse and interpret a trial – trial stats made easy</i> – Dr Natalie Staplin, Senior Statistician, University of Oxford</p> <p><i>Recently reported and ongoing renal trials in the UK – a 2019 update</i> – Fergus Caskey</p>	<p>368 - <i>Prophylactic eculizumab treatment significantly improves renal allograft survival in patients with atypical haemolytic uremic syndrome compared with historic controls</i> – Emily Glover, Newcastle Hospital NHS Foundation Trust</p> <p>30 - <i>Healthcare related activity following kidney transplantation</i> – Eleanor Murray, NHS GGC</p> <p>158 - <i>Donor gender and recipient outcomes after kidney transplantation: a population cohort analysis from the United Kingdom</i> – Georgia Morgan, University of Birmingham</p> <p>253 - <i>What mediates socioeconomic inequity in access to living-donor kidney transplantation? Results from a multicentre case-control study</i> –</p>
-------------	--	---	---	--	---	--	--	---

10:30-12:00	<p>270 - <i>A novel small molecule therapy rescues trafficking of misfolded podocin and corrects Nephrotic Syndrome caused by a common podocin mutation</i> – Valeryia Kuzmuk, University of Bristol</p> <p>446 - <i>A novel P2X7 knockout rat is not protected from experimental glomerulonephritis or vasculitis</i> – Maria Prendecki, Imperial College</p> <p>229 - <i>Analysis of intensified immunosuppression response in genetically-stratified steroid resistant nephrotic syndrome (SRNS) patients predicts outcomes and suggests distinct immune mechanisms</i> – Anna Mason, Bristol Renal, University of Bristol</p>			<p>236 - <i>Self-monitoring of Urine Specific Gravity using Smartphone Applications Promotes Adherence to High Water therapy and facilitates remote data capture in the DRINK Randomised Trial</i> – Ragada El-damanawi, University of Cambridge</p> <p>Co-badged by the BRS Rehab Network and the Renal Nutrition Group</p>		<p>134 - <i>Long Term Effects of Acute Kidney Injury on Chronic Kidney Disease and Patient Outcomes: 3-year Results from a Large Prospective Parallel Group Cohort Study</i> – Isma Kazmi, Centre for Kidney Research and Innovation, Derby</p> <p>316 - <i>How common is contrast induced acute kidney injury (CI-AKI) in patients undergoing coronary angiography and percutaneous coronary intervention (PCI)?</i> – Tracey Salter, Frimley Health NHS Foundation Trust and Epsom and St Helier University Hospital</p>		<p>Pippa Bailey, University of Bristol and North Bristol NHS Trust</p> <p>522 - <i>HLA antibody and Tacrolimus variability in transplant recipients during transition from paediatrics to regional adult units</i> – Shilpa Kaki, Sheffield Kidney Institute</p> <p>50 - <i>Barriers to kidney transplantation in children – ATTOmic prospective national study</i>, Matko Marlais, UCL Great Ormond Street Institute of Child Health</p> <p>525 - <i>Correlation between kidney sizes and split renal function in prospective living kidney donors</i> - Anthony Fenton, University Hospitals Birmingham NHS Foundation Trust</p>
-------------	---	--	--	--	--	--	--	--

12:00-13:00	Moderated poster session						
13:00-14:00	Lunch and Exhibition			BRS Rehab Network meeting	SIMPLIFIED Trial meeting	UK Living Kidney Donation meeting	UKKRC glomerulonephritis clinical study group

TUESDAY 4TH JUNE (continued)

14:00-15:00	Corporate Session – Vifor Pharma Systematic Approaches to Managing Hyperkalaemia Professor Phil Kalra, Consultant Nephrologist, Salford Royal NHS Trust. Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust. Dr Chris Wong, Consultant Nephrologist, Aintree University Hospital NHS Trust. Sharing real world examples of applying hyperkalaemia management in practice, in terms of patients, pathways, and protocols.		Corporate Session – Baxter		Ageing immunity and the kidney <i>Basis of Ageing of the kidney</i> – Professor Paul Shiels, Professor of Geroscience, Institute of Cancer Sciences, MVLS, University of Glasgow <i>Immunosenesence and its management</i> – Sian Henson <i>Immunosuppression in older transplant recipients</i> –Ciara Magee 240 - <i>Characterisation of senescent renal epithelial cells in experimental renal disease reveals transcriptional heterogeneity at a single cell level</i> – Eoin O'Sullivan, University of Edinburgh			
15:10-16:10	Polycystic kidney disease: from mechanisms to personalised management Chair: John Sayer and Maria Fragiadaki <i>From ADPKD cell biology to prediction of clinical progression via urinary exosomal biomarker profiling</i> – Professor Patricia Wilson, Professor Renal Medicine, UCL/Royal Free <i>Advantages of using a genetic risk score to predict the risk of disease progression</i> – Emilie Cornec-Le Call	Kidney Transplantation: improving access, improving outcomes Chair: Kerry Tomlinson and Graham Lipkin <i>Access to transplantation – lessons/findings from ATTOM</i> – Dr Rommel Ravanan, Consultant Nephrologist, Southmead Hospital	Electronic Patient Reported Outcomes (ePROs) – state of the art <i>Symptom monitoring in advanced chronic kidney disease using electronic patient-reported outcomes</i> – Dr Derek Kyte, Lecturer in Health Research Methods, University of Birmingham <i>Towards national collection of ePROs as part of renal services in the UK</i> – Sabine van der Veer	Wasting syndromes in CKD Chair: Tom Wilkinson and Fiona Willingham <i>Proposed mechanisms of muscle wasting in CKD and opportunities for therapeutic intervention</i> – Dr Luke Baker, Post-Doctoral Researcher, University of Leicester <i>Screening and diagnosing wasting conditions in CKD</i> – Dr Clare McKeaveney, Research Fellow, University of Belfast	New drugs for type 2 diabetes – will they protect the heart and the kidneys? <i>It's not just about the sugar – a paradigm shift in the management of type 2 diabetes</i> - Janaka Karalliedde <i>SGLT2 inhibitors in patients with type 2 diabetes and CKD: Results of the CREDENCE study</i> – Professor David Wheeler, Professor of Kidney Medicine, University College London	NICE RRT Guideline: The Key Issues Debated Chair: Jane Dudley <i>HDF should be the standard of care: PRO</i> - Dr James Gilbert, Head of Evidence Reviews, National Guideline Alliance (NICE guideline developer), Royal College of Obstetricians and Gynaecologists <i>HDF should be the standard of care: CON</i> - Dr James Tattersall	Keeping education at the forefront of nephrology training 91 - <i>Trainee led development of a national online renal community</i> – Rhodri Pyart, Cardiff and Vale Health Board 407 - <i>Moving towards a risk based model for timing of pre-dialysis planning: our unit's experience</i> – Stephanie Stringer, University Hospitals Birmingham	Pregnancy in CKD: Difficult Decisions <i>Persisting with pregnancy – a good thing? – Professor Liz Lightstone</i> , Professor of Renal Medicine, Imperial College London 484 - <i>A Study of Maternal and Fetal Outcomes in a Cohort of Pregnant Women with Chronic Kidney Disease</i> – Nadia Sarween, University Hospitals Birmingham

15:10-16:10	<p><i>Challenges of using imaging to predict the risk of progression in the UK</i> – Dr Roslyn Simms, Consultant Nephrologist & Honorary Senior Lecturer in Nephrology, Sheffield Kidney Institute, Northern General Hospital & University of Sheffield</p>	<p><i>Understanding and overcoming the challenges of ethnicity in UK Living Kidney Donation</i> – Professor Caroline Wroe, Consultant Nephrologist, South Tees Hospitals NHS Foundation Trust</p> <p><i>Combined intelligence: What are we learning from GIRFT and Transplant First Visits?</i> – Dr William McKane, Consultant Nephrologist, Sheffield Teaching Hospitals NHSFT and Kerry Tomlinson</p>	<p>18 - <i>Poor advance care planning in older patients with end-stage renal disease: a qualitative interview study of nephrologists</i> – Julien O'Riordan, Galway University Hospital</p> <p>329 – <i>Longitudinal effects of depression on cognitive function in haemodialysis patients</i> – Aghogho Odudu, University of Manchester</p>	<p>244 - <i>A programme of supervised exercise and multidisciplinary education (PREHAB) prevents deterioration in physical function and nutritional status in persons approaching and commencing dialysis</i> – Fiona Willingham, University Hospitals of Derby and Burton NHS Foundation Trust</p> <p>375 - <i>CKD-PAQ: Developing a tool for physical activity estimation in chronic kidney disease</i> – Sivakumar Sridharan, Lister Hospital</p> <p>Co-badged by the BRS Rehab Network and the Renal Nutrition Group</p>		<p><i>Home therapy should be the default: PRO</i> – Professor Jeremy Levy, Consultant Nephrologist, Imperial College Healthcare NHS Trust</p> <p><i>Home therapy should be the default: CON</i> – Dr Andrew Mooney, Consultant Renal Physician and Honorary Clinical Associate Professor, St James' University Hospital</p>	<p>87 - <i>Inspiring a generation: A Renal Taster Weekend for prospective nephrologists</i> – Jemima Scott, North Bristol NHS Trust</p> <p>21 - <i>Developing an in situ simulation programme on renal emergencies to facilitate improvement in multidisciplinary working</i> – Ailish Nimmo, NHS Lothian</p>	<p>94 - <i>Diabetes during pregnancy and congenital genitourinary malformations: A systematic review and meta-analysis</i> – Mounika Parimi, London School of Hygiene and Tropical Student</p> <p>129 - <i>Conception intentions and pregnancy experiences amongst women of childbearing age on dialysis</i> – Phil Webster, Imperial College Healthcare NHS Trust</p>
-------------	---	--	--	--	--	---	---	--

16:10-16:50	Tea/coffee Break and exhibition							
16:50-18:20	<p>Transformational leadership – Examples from practice, Individual to organisational level</p> <p><i>Jane MacDonald leadership lecture</i> – Professor Philip Kalra, Consultant Nephrologist at Salford Royal Hospital,</p>	<p>Vascular Disease and the Kidney</p> <p><i>Endothelial responses to mechanical shear stress' in the vascular disease and the kidney session</i> – Professor Paul Evans, Professor of Cardiovascular, University of Sheffield</p>	<p>Long-term kidney transplant follow up: A Multidisciplinary approach</p> <p><i>Developing a long-term kidney transplant assessment and review clinic: Challenges and Triumphs</i> - Ms Sharon Frame,</p>	<p>Implementing more or less; the challenges of the non-standard haemodialysis schedule</p> <p>Chair: James Burton and Enric Vilar</p> <p><i>Keeping patient choice at the heart of our dialysis provision</i> -</p>	<p>Advances in PD: From basic science to patient experience</p> <p><i>Advances in PD: From basic science to patient experience</i> - Chia Te Liao</p> <p><i>De Wardener Lecture – Individualising the peritoneal dialysis prescription</i> -</p>	<p>Monoclonal gammopathy of renal significance (MRGS), amyloidosis and multiple myeloma: recent advances</p> <p><i>Paraprotein associated kidney diseases: MGRS and beyond</i> - Professor Jean-Paul Fermand</p>	<p>How can routinely collected data improve kidney care?</p> <p>Chair: Dorothea Nitsch and Elizabeth Wallin</p> <p><i>Changes in creatinine after starting RAS blockade: A matter of perspective?</i> – Dr Laurie Tomlinson</p>	<p>Multimorbidity and kidney disease – impact and implications</p> <p>Chair: Simon Fraser and Kristin Veighey</p> <p><i>Chronic Kidney Disease, multimorbidity and inequalities</i> - Professor Paul Roderick</p>

TUESDAY 4TH JUNE (continued)

16:50-18:20	<p>Professor at the University of Manchester</p> <p><i>The National Picture and presentation of work across professional disciplines to improve patient outcomes using transformational leadership</i> – Professor Kim Manley</p> <p><i>Making an Impact on Nursing recruitment and retention</i> – Claire Main</p> <p><i>From HCA to ANP a journey that can be replicated!</i> Victoria Ashworth Advanced Nurse Practitioner Royal Liverpool Hospitals (Video)</p> <p><i>Renal Nurse of the Year:</i> Gail Williams, Welsh Renal Clinical Network Lead Nurse, Welsh Health Specialist Service Committee</p> <p>Co-badged by ANNUK</p>	<p><i>Role of the innate immune system in hypertension & its complications</i> – Dr Bean Dhaun</p> <p><i>Premature vascular ageing drives calcification in CKD</i> – Professor Catherine Shanahan</p> <p><i>Early intervention to prevent microvascular dysfunction of the kidney</i> – Dr Becky Foster</p> <p>445 - <i>Using three-dimensional imaging to study how kidney lymphatic vessels develop</i> – Daniyal Jafree, UCL, Great Ormond Street Institute of Child Health</p>	<p>Clinical Nurse Specialist in Transplantation and Health Promotion</p> <p><i>Cardiovascular disease in long-term kidney transplant recipients</i> – Dr Adnan Sharif, Consultant Nephrologist Queen Elizabeth University Hospital Birmingham</p> <p><i>Non-melanoma skin cancer in long-term kidney transplant recipients: Prevalence and prevention</i> - Dr Mary Wain, Consultant Dermatologist, St. John's Institute of Dermatology, Guy's and St. Thomas' NHS Foundation Trust, London</p> <p><i>Bone Disease after Transplantation</i> - Dr Arif Khwaja, Consultant Physician Sheffield Kidney Institute, Northern General Hospital, Sheffield</p>	<p>Maddy Warren, Dialysis Patient</p> <p><i>Less is more: incremental dialysis schedules</i> - Mo Kamal, Clinical Fellow, Lister Hospital</p> <p><i>Mind the gap: the problem with three times a week in-centre haemodialysis</i> – Dr James Fotheringham, Consultant Nephrologist, Sheffield Kidney Institute</p> <p><i>Doing things differently: the hospital perspective</i> - Suzi Glover, Deputy Head of Nursing, Leicester Hospitals</p> <p>Panel Q&A.</p> <p>453 - <i>The effect of centre practice in initiating haemodialysis by an incremental approach compared to standard practice and short term patient survival</i> – Andrew Davenport, Royal Free Hospital</p>	<p>Professor Edwina Brown, Consultant, Hammersmith Hospital</p> <p><i>The patient experience of PD and switching to HD</i> – Gill Combes</p> <p><i>Impact of clinical practice patterns: Results from P-DOPPS</i> – Dr Mark Lambie, Senior Lecturer and honorary consultant in Renal Medicine, Royal Stoke University Hospital</p> <p>117- <i>Innate immune response biomarkers in peritoneal dialysis effluent as reliable diagnostic indicators of peritonitis - evaluation of a rapid diagnostic test device</i> – Cate Goodlad, Royal Free Hospital</p>	<p><i>Histology - or pathology - of paraprotein-related kidney diseases</i> - Dr Candice Roufosse, Senior Clinical Lecturer Imperial College</p> <p><i>What the nephrologist needs to know about current and new treatments for MGRS, amyloid and myeloma</i> – Professor Ashutosh Wechalekar</p> <p>286 - <i>Renal Outcome in Patients with Newly Diagnosed Multiple Myeloma: Results from the UK NCRI Myeloma XI trial</i> – Ritika Rana, Queen Elizabeth Hospital Birmingham</p> <p>367 - <i>Proliferative glomerulonephritis with non-organised monoclonal immunoglobulin deposits (PGNMID): a single-centre retrospective study</i> – Sarah Blakey, Imperial College NHS Trust</p>	<p>Associate Professor/Honorary Consultant Nephrologist, London School of Hygiene and Tropical Medicine</p> <p><i>Are bisphosphonates safe in CKD?</i> – Professor Dani Prieto-Alhambra</p> <p><i>What does observational research tell us about AKI care?</i> – Dr Simon Sawhney</p> <p>67 - <i>Outcomes in the first 90 days after starting dialysis – transition of the UK Renal Registry to capture of all acute and chronic dialysis sessions</i> – Barnaby Hole, UK Renal Registry</p> <p>474 - <i>Heart failure and AKI after hospital admission with AKI among patients taking ACE inhibitors and ARBs</i> – Patrick Bidulka, London School of Hygiene and Tropical Medicine</p>	<p><i>The impact of multimorbidity on Acute Kidney Injury</i> – Dr Lynne Sykes, Clinical Research Fellow, Salford Royal Foundation Hospital</p> <p><i>Treatment burden and minimally disruptive medicine for people with kidney disease</i> – Professor Frances Mair, Norie Miller Professor of General Practice and Head of General Practice and Primary Care, General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow</p> <p>388 - <i>The Electronic Frailty Index (eFI) Indicates Mortality Risk in End Stage Kidney Disease (ESKD) Patients on Dialysis</i> – Andrew Mooney, St James's University Hospital</p> <p><i>Sponsored by Kidney Research UK</i></p>
-------------	--	--	--	---	---	---	--	---

TUESDAY 4TH JUNE (continued)

16:50-18:20			<p><i>Medication Adherence in long-term kidney transplant recipients - Hayley Wells, Senior Renal Pharmacist, Guy's and St. Thomas' NHS Foundation Trust, London</i></p>	<p>518 - <i>Acceptability of alternate day dialysis regimes to patients on in-centre maintenance dialysis: a multi-centre survey</i> – Enric Vilar, Eastern North Herts NHS Foundation Trust</p> <p>267 - <i>Feasibility of non-contrast cardiac MR stress T1-mapping to assess coronary artery disease in patients on haemodialysis</i> – Federica Poli, University of Leicester</p>		<p>478 - <i>Association between non-malignant monoclonal gammopathy and risk of adverse outcomes in chronic kidney disease</i> – Anthony Fenton, University Hospital Birmingham</p> <p><i>What the nephrologist needs to know about current and new treatments for MGRS, amyloid and myeloma</i> - Professor Ashutosh Wechalekar</p>	<p>248 - <i>A model of cardiovascular disease in people with reduced renal function using routine healthcare data</i> – Claire Simons, University of Oxford</p>	<p>108 - <i>Temporal trends in prevalence of chronic kidney disease in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016</i> – Hilda Hounkpatin, University of Southampton</p> <p>212 - <i>Prognostic accuracy of frailty screening methods in advanced chronic kidney disease</i> – Andrew Nixon, Lancashire Teaching Hospitals NHS Foundation Trust</p>
-------------	--	--	--	---	--	--	---	--

18:25-19:05 **Highlights of Day Two**

19:40 **Conference dinner**

WEDNESDAY 5TH JUNE

0.322917

Registration opens

07:45-08:45

Renal Association AGM

08:45-10:00

Plenary Session

Chair: Graham Lipkin and Maarten Taal

End of life care in chronic disease: Lessons for the kidney care community

Baroness Ilora Finlay, Professor of Palliative Medicine at Cardiff University and Independent Crossbench member of the House of Lords

Raine Lecture*The psychosocial health of young adults on renal replacement therapy-* Dr Alexander Hamilton, Clinical Lecturer in Renal Medicine, University of Bristol/North Bristol NHS Trust**Mallick Lecture***Upstream to the Reservoir* - Karen Jenkins, Consultant Nurse, Kent Kidney Care Centre

10:00-10:30

Tea/coffee break and exhibition

10:30-12:00

<p>Vascular access: current challenges, future solutions</p> <p>Chair: Saheed Ahmed and Paul Gibbs</p> <p><i>Interventional Nephrology training my experience East to West</i> - Dr Rauri Clark</p> <p><i>Should Nephrologist do Fistuloplasty?</i> - Dr David Lewis, Consultant Nephrologist, Salford Royal NHS Foundation Trust</p> <p><i>What the UK can learn from ASDIN</i> - Professor Asif Arif, Chair: Department of Medicine, Jersey Shore University Medical Center</p>	<p>Living well with frailty and CKD</p> <p>Chair: Helen Hurst and Andrew Nixon</p> <p>Hannah Young, Senior Physiotherapist, NIHR Doctoral Research Fellow, University Hospitals of Leicester /University of Leicester</p> <p>Professor Edwina Brown, Consultant, Hammersmith Hospital</p> <p>Dr James Tollitt, Renal Research Fellow, Salford Royal NHS Foundation Trust</p>	<p>Diabetic nephropathy from inflammation to fibrosis</p> <p>Chair: Becky Foster and Indranil Dasgupta</p> <p><i>Targeting the glomerular vasculature as a treatment for diabetic nephropathy</i> – Professor Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, School of Cardiovascular Medicine & Science, King’s College London and Guy’s and St Thomas NHS Foundation Trust</p> <p><i>Transglutaminase 2: A therapeutic target in renal fibrosis</i> – Professor Tim Johnson</p>	<p>Quality Improvement – the best of the best from the UK kidney community</p> <p>Chair: Elizabeth Wallin</p> <p><i>What does a successful Quality Improvement project look like? Lessons from the front line</i> – Dr Amanda Newnham, Consultant Paediatric Nephrologist, Leeds Children’s Hospital</p> <p><i>439 - A paediatric AKI service: Improving recognition and reducing incidence</i> – Grace McCall, Manchester University Hospitals</p>	<p>Equal opportunities and diversity</p> <p><i>Equal opportunities in Nephrology (EON) UK survey findings</i></p> <p>- Dr Bhauna K Pandya, Chair EON Committee, Consultant Nephrologist, Aintree University Hospital NHS Foundation Trust</p> <p><i>LTFT and gender pay gap</i></p> <p>- Lucy Grant, Senior Policy Advisor, BMA</p> <p>Diversity in the NHS - Speaker TBC</p> <p>Round Table discussions facilitated by Baroness Finlay</p>	<p>Patient involvement in service provision, quality improvement and research</p> <p><i>Patient involvement - why is it so important – Mr Simon Denegri OBE, NIHR National Director for Patients, Carers and the Public</i></p> <p><i>Kidney Community Patient Involvement quality standards: results of the NIHR INVOLVE Test bed project</i> – Professor Paula Ormandy, Professor Long term conditions research, British Renal Society Vice President for Research, University of Salford and Mr David Coyle</p>	<p>Glomerulonephritis abstracts</p> <p>341 - <i>Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis – A randomised controlled trial</i> – Aikaterini Nikolopoulou, Imperial College Healthcare NHS</p> <p>497 - <i>Long-term follow up of a steroid-minimising regimen for remission-induction in ANCA associated vasculitis</i> – Dr Stephen McAdoo, Consultant Nephrologist, Imperial College London</p>
--	---	--	--	--	---	--

<p><i>Establishing Access in Central Vein Occlusion - The Surfacar System</i> - James Gilbert, Consultant Transplant & Vascular Access Surgeon, Vascular Access Lead Training Programme Director Core Surgery HETV Oxford Transplant Centre</p> <p><i>Update on DCB use in the AV Access circuit</i> – Dr Kate Steiner</p> <p><i>Update on EndoAVFs in the UK and Wider World</i> - Dr. Aurang Zaib Khawaja, Department of Renal transplant surgery and dialysis access</p>	<p>Learning Outcomes: Understand what frailty is and why it is relevant for patients with CKD. Understand the Comprehensive Geriatric Assessment (CGA) including cognitive impairment, interventions and implications for patients living with frailty and CKD. Through case study exemplars, understand how frailty identification and the principles of the CGA can inform shared decision making and advanced care planning</p> <p>BRS/RA Education</p>	<p><i>What is new with the podocyte and diabetes?</i> – Professor Richard Coward</p> <p>415 – <i>The functional consequences of myocardial fibrosis in chronic kidney disease</i> – Manvir Hayer, University Hospitals Birmingham</p> <p>156 - <i>A novel heparanase inhibitor protects glomerular endothelial glycocalyx during diabetes mellitus</i> – Monica Gamez, The University of Bristol</p> <p>512 - <i>Identification of high-risk patient clusters based on extracellular matrix turnover</i> – Paul Cockwell, Queen Elizabeth Hospital Birmingham</p>	<p>113 - <i>Acute Kidney Disease - a new definition, but is it useful in describing renal outcomes following AKI?</i> – Isma Kazmi, Centre for Kidney Research and Innovation, Derby</p> <p>486 - <i>Wide variance in transport provision for patients receiving in centre or satellite haemodialysis treatment in the UK: results of a national survey</i> – Paul Cockwell, Queen Elizabeth Hospital Birmingham</p> <p>454 - <i>Partnership working to provide bespoke renal welfare and debt management service</i> – Clara Day, University Hospitals Birmingham NHS Foundation Trust</p> <p>381 - <i>Increasing the prevalence of shared haemodialysis care at Salford Royal Foundation Trust dialysis units</i> – Emma Jenner, Salford Royal Foundation Trust</p>		<p><i>Getting it right first time – the reality of meaningful patient and public involvement</i> - Mr Andy Henwood and Prof Nicki Thomas</p> <p>370 - <i>Do clinical staff activate patients? The relationship between Clinician Support for Patient Activation and the Patient Activation Measure in In-centre haemodialysis patients</i> – Maria Keriakos, Sheffield Kidney Institute</p> <p>417 - <i>What information do staff use to involve patients in decisions about conservative management? A critical review of leaflets used in UK renal services</i> – Anna Winterbottom, Leeds Teaching Hospitals</p> <p>53 - <i>Co-producing progression criteria for feasibility studies: a partnership between patient representatives, clinicians and researchers</i> – Hannah Young, Senior Physiotherapist NIHR Doctoral Research Fellow, University Hospitals of Leicester /University of Leicester</p>	<p>449 - <i>The effect of P2X7 antagonism on nephrotoxic nephritis</i> – Maria Prendecki, Imperial College</p> <p>359 - <i>Live glomerular imaging in experimental crescentic glomerulonephritis reveals sequential glomerular infiltration of monocyte subsets with distinct effector functions</i> – Tabitha Turner-Stokes, Imperial College</p> <p>389 - <i>Chorioretinal thickness tracks disease activity in clinical ANCA vasculitis</i> – Tariq Farrah, University of Edinburgh</p> <p>215 - <i>Histological findings in acute interstitial nephritis – a role for scoring non-fibrotic inflammation</i> – Emma Cannon, Queen Elizabeth University Hospital, Glasgow</p> <p>325 - <i>Myeloperoxidase inhibition: potential therapeutic target for crescentic glomerulonephritis?</i> – Marilina Antonelou, University College London</p>
---	---	---	---	--	--	---

WEDNESDAY 5TH JUNE (continued)

10:30-12:00				<p>494 - <i>Standards for Transport Provision for Patients receiving in centre or satellite unit haemodialysis: Finding a Way Together</i> – Paul Cockwell, Queen Elizabeth Hospital Birmingham</p> <p>82 - <i>Reducing inpatient admissions by ambulating care for patients with acute kidney injury (AKI)</i> – Nicholas Annear, St George's University Hospitals NHS Foundation Trust</p>		<p>495 - <i>Fostamatinib treatment of a new model of MPO-ANCA vasculitis in WKY rats induced by administration of a sub-nephritogenic dose of nephrotoxic serum after immunisation with human myeloperoxidase</i> – Stephen McAdoo, Imperial College London</p> <p>242 - <i>Signalling Response Under Par: A PAR-1 mediated signalling pathway in podocytes is a consistent feature of 'circulating factor' initiated nephrotic syndrome</i> – Carl May, Bristol Renal</p>
12:10-13:10	<p>Corporate Session – Vifor Pharma</p> <p><i>Renal Anaemia – Is it time for change?</i></p> <p>Professor Chris Probert, Professor of Gastroenterology Cellular and Molecular Physiology, Royal Liverpool Hospital.</p> <p>Dora Pereira, Researcher and Medical Advisor for Vifor Pharma.</p> <p>Dr Indranil Dasgupta, Consultant Nephrologist, Heartlands Hospital Birmingham.</p> <p>The symposium looks at 3 hot topics in renal anaemia, challenging current thinking. Is it time for change? Includes:</p> <ul style="list-style-type: none"> - Gut microbiome and the impact this can have on CKD patients. - The science behind irons – are all irons the same? - The Pivotal trial – changing practice. 			<p>Corporate Session – Syner Med</p> <p><i>Developments in vascular access practice in challenging haemodialysis patients</i></p> <p>Chair and Speaker – Dr Mick Kumwenda, Consultant Nephrologist, Glan Clwyd Hospital, Rhyl</p> <p>Mr Paul Gibbs, Consultant Vascular Access and Transplant Surgeon, Wessex Kidney Centre, Queen Alexandra Hospital, Portsmouth. President of VASBI.</p> <p>Margaret Aitken, Vascular Access Clinical Nurse Specialist, Queen Elizabeth Hospital, Glasgow</p> <p>Chair: VASBI Nurses Section, Co Chair: MAGIC</p>	<p>Mechanisms of tubulointerstitial injury</p> <p><i>The collecting duct: A critical protector against renal tubulointerstitial injury?</i> - Dr Qihe Xu, Senior Lecturer in Renal Medicine, King's College London</p> <p><i>Collecting duct contribution to development, injury and repair</i> - Dr Joan Li, Senior Researcher, Lecturer, University of Queensland</p>	

13:10-14:10	Lunch and exhibition						
14:10-15:10	Moderated Poster Session						
15:15-16:15	<p>Late breaking abstracts</p> <p>SIX ABSTRACT PRESENTATIONS</p>	<p>Epigenetic regulation in kidney disease</p> <p><i>Dynamics of DNA promoter methylation in progression of chronic kidney disease – Professor Michael Zeisberg</i></p> <p><i>The relevance of CD44 alternative splicing in the regulation of pro-fibrotic and anti-fibrotic cell functions in CKD – Dr Soma Meran</i></p> <p>423 - <i>RNA regulation in renal disease: mutations in the ribonucleoproteins dyskerin and NOP10 are associated with a novel nephrotic syndrome – Jennie Chandler, Great Ormond Street Institute of Child Health</i></p> <p>241 - <i>Adeno-Associated Virus Vector Gene Therapy Ameliorates Nephrosis in a Podocin-deficient Mouse Model of Nephrotic Syndrome – Wen Yi Ding, University of Bristol</i></p>	<p>Crouching Tiger– Hidden trauma Hidden Psychological Trauma in Renal Patients- Its relevance and its treatment</p> <p>Chair: Siobhan Commins and Amanda Bevin</p> <p><i>Exploring Early Trauma in Altruistic Donors - Angela Taylor - Lead Specialist Renal Counsellor, Brighton and Sussex University Hospitals NHS Trust</i></p> <p><i>EMDR a Psychological Trauma Intervention in the Renal Setting – Maria Tribe, Renal Psychotherapist/Counsellor, Brighton and Sussex University Hospitals NHS Trust and Jane Sudlow - Specialist Renal Psychotherapist/Counsellor or Brighton and Sussex University Hospitals NHS Trust</i></p> <p><i>Hidden Trauma in AKI patients – Juliet Davies - Specialist Renal Psychotherapist /Counsellor, Kings</i></p>	<p>Supporting the development of nephrology in low and middle income countries</p> <p>Chair: Jennie Jewitt-Harris and Iain MacPhee</p> <p><i>Africa - Dr Gavin Dreyer</i></p> <p><i>India - Dr Debasish Banerjee</i></p> <p><i>Bosnia - Dr Aimun Ahmed</i></p>	<p>Improving the management of AKI for the population</p> <p><i>Welcome and opening - Dr Richard Fluck, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust and Chair of Think Kidneys</i></p> <p><i>Data and linking data – changes in practice leading to changes in outcomes CCG reporting update GIRFT using AKI data What comes out of the AKI analysis over the next three months HES linkage - James Medcalf, Consultant Nephrologist, University Hospitals of Leicester</i></p> <p><i>Education: RCGP AKI Project – Dr Jon Murray, Consultant Nephrologist, James Cook University Hospital, Middlesbrough and Dr Tom Blakeman, GP and Clinical Senior Lecturer in Primary Care, University of Manchester</i></p>	<p>Clinico-Pathological Correlation Linking clinical disease, pathology, and treatment</p> <p>Chair: Nick Torpey and Ailish Nimmo</p> <p>Professor Terry Cook</p> <p>79 - <i>Focal segmental necrotising glomerulonephritis associated with selective IgA deficiency: two case reports – Madelena Stauss, Royal Preston Hospital, Lancashire Teaching Hospitals</i></p> <p>528 - <i>An Unusual Infiltrative Cause of Acute-on-Chronic Kidney Injury – Subash Somalanka, St Helier Hospital</i></p>	<p>Strategies to influence gut microbiota imbalance and its importance in kidney disease</p> <p><i>The gut microbiome in CKD: friend or foe? – Dr Bjorn Meijers, Consultant Nephrologist, Leuven, Belgium</i></p> <p>167 - <i>Comparing active lifestyle intervention using renal dietician-led behaviour change techniques versus standard of care after kidney transplantation (CAVIAR): a randomised controlled trial – Kulli Kuningas, University Hospitals Birmingham</i></p> <p>12 - <i>Skin autofluorescence and malnutrition as predictors of mortality in dialysis patients – Daniela Viramontes Horner, University of Nottingham</i></p> <p>Renal Nutrition Group Co-badged Session</p>

WEDNESDAY 5TH JUNE (continued)

15:15-16:15			College Hospital NHS Foundation Trust		<p><i>Linking with other work – TAKI, NW, other improvement initiatives Educational package and care patterns - Dr Nick Selby, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust</i></p> <p><i>Q&A discussion panel - Dr Richard Fluck, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust and Chair of Think Kidneys</i></p>		
16:20-16:50	<p>Plenary Session:</p> <p><i>A special finale : Charles Pusey - a Lifetime in vasculitis research (Osman Lecture 2019) - Professor of Medicine, and Head of the Renal Section in the Department of Medicine at Imperial College London.</i></p>						
16:50-17:30	<p>Highlights of Day Three and conference close</p>						
17:00	<p>Tea/Coffee (with take away cups available)</p>						

END OF CONFERENCE